Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Novel Hormone Strategies Gain Ground in Breast Cancer

Anita T. Shaffer @Shaffer1
Published: Thursday, Nov 16, 2017
Hope Rugo, MD

Hope Rugo, MD
Although hormone-targeting therapies have been a long-established strategy for the treatment of estrogen receptor (ER)-positive breast cancer, more than 20% of patients with early-stage disease relapse and those who progress to a metastatic stage eventually die from their illness.1

Resistance to endocrine therapy in patients with ER-positive breast cancer is defined in 2 ways 2 :
  • Primary resistance: recurrence within adjuvant therapy or disease progression less than 6 months after treatment
  • Acquired resistance: recurrence at least 12 months after completion of adjuvant therapy or progression 6 months or more after the initiation of endocrine therapy in the metastatic setting
Several key mechanisms of endocrine resistance have been identified, including the PI3K/AKT/ mTOR growth factor signaling network, cyclindependent kinase (CDK) signaling, and histone deacetylase (HDAC) activity. Strategies aimed at these processes have been among the most active attempts to boost the efficacy of endocrine therapies (Figure).1,2


Figure. Targeting Endocrine Therapy Resistance

Figure. Targeting Endocrine Therapy Resistance
Ingrid A. Mayer, MD, MSCI, co-leader and clinical director of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center, distinguished between mechanisms of primary and acquired resistance during a presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in June.2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication